Elevated IL-6 levels in serum and synovial fluid have been detected in patients with rheumatoid arthritis (RA). Regarding the higher concentrations of IL-6 in SF, they showed that the source of IL-6 was inflammation of the joint caused by RA. The normal summary consists of the inner lining layer and the articulated lining. In RA, thickening of the inner lining layer, lymphocytic infiltration, formation of lymphoid follicles, and increased blood vessels are observed. Normal inner lining consists of macrophages από derived from bone marrow…. Type A arthritis and by (FLSs) fibroblasts {home} type B arthritis}.

Type A arthritis is mainly caused by factors such as TNF and FLS that mainly produce IL-6. The development and activation of FLSs stimulated by TNF and IL-6} creates thickening of the inner lining, but also produces MMP, RANKL, VEGF, GM-CSF and IFN. These, in turn, cause arthritic symptoms such as joint pain, swelling, bone erosion and cartilage damage.

IL-6 is released systematically and causes systemic symptoms such as fatigue, anemia and acute phase reactions. Also, IL-6 induces immune activation by activating the vicious cycle of scalable activity of RA disease.

NOTE

The exclusion both of TNF and IL-6 supress arthritis. This can also be done with bioactive substances that have been studied by specialized clinical doctors and have been shown to have no side effects. Konstantinion Research Center has investigated 13 cytokines (IL-16, IFN-γ, IL-2, IL-10, IL-8, IL-6, IL-4, IL-5, IL-1b, TNF-a, IL -12, IL-17A, IL-23) and by spreading the knowledge of the immunology of cytokines in clinical physicians in Greece and abroad, a better daily targeted effective and targeted treatment can be  achieved for most diseases.

ΑΤΤΕΝΤΙΟΝ: Konstantinion Research Center runs all 13 cytokines routinely the last 10 years and knows how to explain the pathology and symptoms of the patients. Therefore, looking for partners that seek these specific tests for clinical laboratorial coolaboration.

Bibliography

Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000; 59 Suppl 1:i21-7.2.

Kishimoto T. The biology of interleukin-6. Blood 1989; 74(1):1-10.

Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8(4):345-50.

Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58(4):1197-200.